RxDoctor Payments Data

Sapan Talati, MD

Interventional Cardiology · Cedar Knolls, NJNPI 1083862601

Payments from drug & device makers

$9,067in general payments, 2019–2025

Across 466 payments — averaging $19.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Boehringer Ingelheim$902
  • AstraZeneca$752
  • Novartis$600
  • Pfizer$534
  • Merck$518
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,055100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,067 in reported general payments places this provider in the 45th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,378,645
Medicare patients
2,949
Services billed
17,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban602$668,298
EntrestoSacubitril/Valsartan174$224,299
XareltoRivaroxaban130$185,721
Repatha SureclickEvolocumab124$114,258
JardianceEmpagliflozin80$105,150
FarxigaDapagliflozin Propanediol75$95,320
MultaqDronedarone Hcl42$55,886
VerquvoVericiguat36$38,370
BrilintaTicagrelor34$30,860
VascepaIcosapent Ethyl48$27,427
Metoprolol Succinate1,321$17,772
Atorvastatin Calcium1,112$11,452
Icosapent Ethyl35$9,292
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,683
Losartan Potassium526$5,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$534$668,298602 claims
NovartisEntresto$600$224,299174 claims
Johnson & JohnsonXarelto$201$185,721130 claims
AstraZenecaFarxiga, Brilinta$752$126,180109 claims
Boehringer IngelheimJardiance$902$105,15080 claims
Sanofi-aventis U.S. LLCMultaq$428$55,88642 claims
MerckVerquvo$518$38,37036 claims
GSKTrelegy Ellipta$41$7,68312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Cedar Knolls

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →